ANDA Review Time Cuts Possible Without User Fees, Barr Rep Says

FDA's Office of Generic Drugs could reduce ANDA review times by adding 50 full time equivalents, Barr Laboratories CEO Bruce Downey told the House Energy & Commerce/Health Subcommittee June 13.